Bristol-Myers Squibb stock

BMY · NYSE · USD

Compare Bristol-Myers Squibb
$63.43Change from previous close: +1.78%Absolute change: +$1.11

Close · November 13, 2026

Price history

+30.43% over the period

1 year: from $48.63 (November 13, 2025) to $63.43 (November 13, 2026), +30.43%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$63.43
October 30, 2026$62.48
September 30, 2026$62.40
August 31, 2026$66.81
July 31, 2026$65.31
June 30, 2026$57.62
May 29, 2026$57.18
April 30, 2026$60.59
March 31, 2026$60.65
February 27, 2026$62.37
January 30, 2026$55.05
December 31, 2025$53.94
November 28, 2025$49.20
November 13, 2025$48.63

At a glance

  • The company

    Discovers, develops and markets biopharmaceutical products for oncology, hematology, immunology, cardiovascular and neuroscience indications

  • Latest results

    Quarter to September 30, 2026 · EPS $1.35 (estimate $1.09)

TickerLandia's take on Bristol-Myers Squibb

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$45.27
52-wk high$68.64

−7.59% from the 52-week high

Analysts · 28 analysts

Average target$65.25+2.87% vs. price

Buy 11 · Hold 16 · Sell 1 · Buy

TickerLandia Fingerprint: Bristol-Myers Squibb

Compared with similar companies: low earnings stability.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Bristol-Myers Squibb is priced as in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Bristol-Myers Squibb's P/E today is 18.3, in line with the median of its last 8 fiscal years (21.0; between 13.3 and 100.5 from 2016 to 2025). Bristol-Myers Squibb's P/E (trailing 12 months): 14.1, −67% against the median of a group of 10 similar companies (42.3).

P/E compared with its history

Compared with 10 similar companies

Bristol-Myers Squibb's metrics compared with similar companies
MetricBristol-Myers SquibbPosition in the groupBand
P/E (trailing 12 months)14.1Low
Forward P/E9.47Low
Operating margin32.4%Middle
ROE44.0%High
Debt/equity1.91High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Bristol-Myers Squibb. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$12.97B

Latest quarter · Q2 2026

Net income

$3.32B

Latest quarter · Q2 2026

Quarterly net margin

25.6%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$129.66B
P/E
14.1
EPS
$4.51
Volume
9.27M
Daily trading
€568.43M
Dividend yield
3.97%
Last ex-dividend on October 2, 2026

How Bristol-Myers Squibb is changing

All results
  • Revenue grew 2.5% a year on average over the last 5 years

  • Operating margin rose from 19.8% to 31.2%

  • Shares outstanding down 9.7% in 5 years

Returns

Bristol-Myers Squibb returns with dividends

$1,000 invested in Bristol-Myers Squibb 5 years ago, on November 15, 2021, would be worth $1,308 today with dividends reinvested: +30.83% in total, +5.53% per year. On price alone it would be $1,064 (+6.39%).

PeriodBristol-Myers SquibbS&P 500$1,000 becomes
1 month+11.93%−3.12%$1,119
6 months+12.48%+1.58%$1,125
Year to date+17.59%+10.46%$1,176
1 year+36.20%+12.23%$1,362
3 years+45.65%+71.41%$1,457
5 years+30.83%+61.48%$1,308
10 years+60.15%+249.40%$1,602

Over the last 6 months it has done better than 40% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Bristol-Myers Squibb: technical analysis

Bristol-Myers Squibb is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 21.8% below its highest close since January 2, 1990 ($81.13, December 2, 2022).

Trend
Upward
RSI (14 sessions)
56
Between 30 and 70
vs 200-session average
+5.12%

Support and resistance

Price areas where Bristol-Myers Squibb has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$68.33+7.72%3 touches, last on September 3, 2026
  2. Resistance$63.86+0.68%2 touches, last on October 22, 2026
  3. Last price$63.43
  4. Support$62.54−1.40%4 touches, last on August 12, 2026
  5. Support$60.42−4.74%5 touches, last on October 29, 2026
  6. Support$59.06−6.90%2 touches, last on June 30, 2026

Volatility and risk

Over the last year it has moved little with the S&P 500.

Beta (1 year) vs S&P 500
0.23
Volatility (60 sessions, annualised)
27.6%
Largest fall in the last year
−16.77%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Bristol-Myers Squibb: seasonality

Average monthly price change over 37 years

−2.0%Jan+0.7%Feb+0.3%Mar−1.2%Apr+1.3%May+0.7%Jun−0.2%Jul−0.2%Aug+1.0%Sep+2.1%Oct+2.7%Nov+2.2%Dec

Over the last 37 years, the strongest month for Bristol-Myers Squibb has been November: +2.67% on average, positive in 25 years out of 36. The weakest has been January: −1.99% on average, positive in 15 years out of 36.

Show chart data
MonthAverageMedianPositive years
January−1.99%−1.45%15 of 36
February+0.67%+0.62%22 of 37
March+0.25%+1.72%22 of 37
April−1.18%−0.88%17 of 37
May+1.32%+0.68%21 of 37
June+0.66%+1.67%22 of 37
July−0.16%−0.97%14 of 37
August−0.22%+1.30%21 of 37
September+0.96%+0.45%19 of 37
October+2.08%+1.95%22 of 37
November+2.67%+1.84%25 of 36
December+2.16%+2.28%22 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Bristol-Myers Squibb and its competitors

Doctors and patients treated for cancer, blood disorders, immune diseases, heart conditions and neurological illnesses are the core of the business of Bristol-Myers Squibb Company, which discovers, develops, manufactures and sells biopharmaceutical drugs worldwide. Key brands include Opdivo, Eliquis, Revlimid, Breyanzi and Zeposia, with products such as Cobenfy for schizophrenia and Camzyos for obstructive heart disease. Sales reach customers through a broad network of intermediaries and care providers, and the United States accounts for 69.1% of revenue, with 28.7% from other countries and 2.3% from other regions.

Headquarters
Princeton, United States
Employees
32,500
Founded
1887
Chief executive
Christopher Boerner
Bristol-Myers Squibb and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Bristol-Myers SquibbBMY$129.66B32.4%14.1+12.48%
PfizerPFE$164.67B29.1%41.3+11.29%
Gilead SciencesGILD$208.48B38.2%—+26.33%
AmgenAMGN$251.89B34.1%27.0+38.41%
Merck & Co.MRK$364.26B35.2%147.8+30.24%
BiogenBIIB$37.46B23.5%108.3+23.89%

Same industry or related industries, similar size. Compare Bristol-Myers Squibb with its competitors · Full profile